Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma

Table 4 Relationship between the activation status of ALK, AKT and mTOR and the clinical features

	ALK		p-value	p-AKT		p-value	p-mTOR		p-value
	+ (n = 62)	- (n = 41)	p-value	+ (n = 54)	- (n = 17)	p-value	+ (n = 57)	- (n = 14)	p-value
Age (years)
Median	17	48		28	29		25	40.5
Range	4–68	16–74	0.000*	4–74	4–65	0.877	4–74	21–65	0.076
Gender
Male	40	27		41	14		44	11
Female	22	14	0.889	13	3	0.573	13	3	0.912
Symptoms
A	38	26		36	11		35	12
B	24	15	0.828	18	6	0.889	22	2	0.068
Lesions
Nodal	44	27		42	12		46	8
Extranodal	18	14	0.583	12	5	0.547	11	6	0.07
Ann Arbor stage
I ~ II	29	21		26	9		28	7
III ~ IV	33	20	0.659	28	8	0.730	29	7	0.953

*Statistically significant value.
Symptom B, systemic symptoms of fever, night sweats, and weight loss; Symptom A, absence of the systemic symptoms.

ISSN: 1471-2407